Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q4 2024 Earnings Presentation
25 slides from Acadia Pharmaceuticals's earnings presentation, Feb 26, 2025
Slide 1: Fourth Quarter 2024 Earnings Call
Fourth Quarter 2024 Earnings Call FEBRUARY 26, 2025
Slide 2: Call Agenda
Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Catherine Owen Adams | Chief Executive Officer Commercial Update Tom Garner | Executive Vice President, Chief Commercial Officer R&D Update Elizabeth H.Z. Thompson | Executive
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will
Slide 4: Opening Remarks
Opening Remarks Catherine Owen Adams CHIEF EXECUTIVE OFFICER 4
Slide 5: ACADIA Highlights
ACADIA Highlights Commercial R&D Financial Delivering strong Submitted MAA in the Further strengthened financial results for both EMA for trofinetide balance sheet with sale of DAYBUE & NUPLAZID Priority Review Voucher Announced a second indication Guiding 2025 to >$1B for ACP-204 in Lewy Body Demen
Slide 6: Commercial Brand Highlights
Commercial Brand Highlights DAYBUE NUPLAZID Q4 2024 sales of $96.7 million, Q4 2024 sales of $162.9 million, up 11% year over year 6% sequentially up 13% year over year FY 2024 DAYBUE sales of $348.4 million, up FY 2024 NUPLAZID sales of $609.4 from $177.2 million in 2023 million, up 11% from 2023 S
Slide 7: Deep and Diverse Pipeline Across CNS and Rare Disease
Deep and Diverse Pipeline Across CNS and Rare Disease PROGRAM INDICATION MECHANISM OF ACTION DISCOVERY IND ENABLING PHASE 1 PHASE 2 PHASE 3 LAUNCHED CNS NUPLAZID Parkinson's Disease Psychosis 5HT2A inverse agonist ACP-204 Alzheimer's Disease Psychosis New 5HT2A inverse agonist ACP-204 Lewy Body Deme
Slide 8: Commercial Update
Commercial Update Tom Garner CHIEF COMMERCIAL OFFICER 8
Slide 9: DAYBUE Q4 Update
DAYBUE Q4 Update KEY Q4 TRENDS $96.7M ▷ 920 unique patients received DAYBUE in Q4 in Q4 Net Product Sales ▷ 62% active patients have now been on therapy 12 Up 11% vs. Q3 2024 months or longer ▷ Continued sequential QoQ volume growth (throughout 2024) in paid bottles – with continuing patients $348.4
Slide 10: Our 2025 strategies are designed to unlock the potential that DAYBUE offers
Our 2025 strategies are designed to unlock the potential that DAYBUE offers UNITED STATES | Est 6,000-9,000 prevalent patients EU | Est 9,000 – 12,000 prevalent patients ▷ Evolved customer model with ~30% larger footprint to ▷ Anticipated Q1:2026 approval expand coverage outside of COE's where ~65%
Slide 11: NUPLAZID Q4 & FY24 Update
NUPLAZID Q4 & FY24 Update $162.9M in Q4 Net Product Sales LEVERAGING PUBLISHED REAL-WORLD EVIDENCE 1-3 Up 13% year-over-year; highest ever quarterly sales ▷ Associated with lower all-cause mortality, hospitalizations, ER visits, and shorter length of stays vs. atypical antipsychotics $609.4M EDUCATI
Slide 12: NUPLAZID Growth Outlook
NUPLAZID Growth Outlook Activate Consumers Drive Market Share Increase field force efficiency Pull through interested Further leverage consumers from branded real world evidence to drive Leverage AI and data to DTC campaign prescriber decisions call on the right prescribers at the right time NUPLAZI
Slide 13: R&D Update
R&D Update Elizabeth H.Z. Thompson E X E C U T I V E V I C E P R E S I D E NT | H E A D O F R E S E A R C H A ND D E V E L O P M E NT 13
Slide 14: Trofinetide ROW Regulatory Update
Trofinetide ROW Regulatory Update EU Japan Submitted MAA for Continue productive trofinetide to EMA discussions with PMDA Anticipating EMA approval in Expect to begin a required the first quarter of 2026 Phase 3 study in Japanese Rett syndrome patients in Q3 2025 14
Slide 15: ACP-101 in Prader Willi Syndrome
ACP-101 in Prader Willi Syndrome PHASE 3 STUDY DESIGN Prader-Willi Syndrome: ▷ Rare genetic disorder caused by a deletion or mutation ACP-101 on chromosome 15 (Intranasal carbe=tocin) 3.2mg ▷ Hyperphagia is a defining characteristic of PWS distinguished by unrelenting hunger ▷ Affecting ~8,000 – 10,
Slide 16: ACP-204 Builds Upon but is Structurally Distinct from Pimavanserin
ACP-204 Builds Upon but is Structurally Distinct from Pimavanserin ACP-204 ADP-204 TARGET PRODUCT PROFILE Mitigate or eliminate QT prolongation Enable doses higher than pimavanserin 34 mg equivalent Improve time to onset of action ACP-204 FEATURES A COMBINATION OF STRUCTURAL CHANGES VS PIMAVANSERIN,
Slide 17: RADIANT Phase 2 / Phase 3
RADIANT Phase 2 / Phase 3 PHASE 2 N=318, double-blind, TWO PHASE 3 STUDIES of similar size and design randomized 1:1:1 Global, placebo-controlled, double-blind Phase 2 enrolling S E A MLE S S E NROLLM E NT patients with Alzheimer’s disease psychosis (ADP) ACP-204 (60mg) ▷ Approximately 30% of patien
Slide 18: Lewy Body Dementia (LBD)
Lewy Body Dementia (LBD) Associated with abnormal deposits of alpha-synuclein in the brain1 >1 million people in the U.S may be living with LBD; 50% -75% of people with LBD experience psychosis (Lewy Body Dementia Psychosis or LBDP)2 ▷ Approximately 200,000 patients living with LBD are being treated
Slide 19: ACP-711 Planned Phase 2 in Essential Tremor
ACP-711 Planned Exclusively licensed from Saniona in November 2024 Phase 2 in Essential Tremor ACP-711 is a potential first-in-class, highly selective GABAA α3 positive allosteric modulator (PAM) with potential to treat essential tremor Essential tremor is characterized by shaking or trembling movem
Slide 20: Financial Update
Financial Update Mark Schneyer CHIEF FINANCIAL OFFICER 20
Slide 21: Q4 and FY 2024 Financial Highlights
Q4 and FY 2024 Financial Highlights YoY YoY Millions, Except EPS 4Q24 4Q23 FY24 FY23 Change Change TOTAL Revenue $259.6 $231.0 12% $957.8 $726.4 32% NUPLAZID $162.9 $143.9 13% $609.4 $549.2 11% DAYBUE $96.7 $87.1 11% $348.4 $177.2 97% R&D $100.7 $66.7 51% $303.2 $351.6* (14%) SG&A $130.1 $111.5 17%
Slide 22: Introducing FY 2025 Financial Guidance
Introducing FY 2025 Financial Guidance FY24 Results FY25 Guidance NUPLAZID Net Sales $609.4 Million $650 to $690 Million NUPLAZID Gross-to-Net 26.1% 22.5% to 25.5% DAYBUE Net Sales $348.4 Million $380 to $405 Million DAYBUE Gross-to-Net 18.8% 21.5% to 24.5% Total Revenue $957.8 Million $1.03 to $1.0
Slide 23: Concluding Remarks
Concluding Remarks Catherine Owen Adams = CHIEF EXECUTIVE OFFICER 23
Slide 24: 2025-2026 Anticipated Milestones
2025-2026 Anticipated Milestones 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Anticipated Filed MAA Managed Access Programs Approval in with EMA available in certain EU countries EMA ACP-101 Phase 3 Phase 3 Potential LAST PATIENT IN TOPLINE RESULTS Approval (PWS) Phase 2 Phase 2 Phase 2 ACP-204 in LBDP in ADP
Slide 25: Q&A Session
Q&A Session 25
ACADIA Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix